Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Fareston
Fareston 60 mg tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-085621 · Präparat HOS-083163
Theoretically the metabolism of toremifene is inhibited by drugs known to inhibit the CYP3A enzyme
system which is reported to be responsible for its main metabolic pathways. Examples of such drugs
are antifungal imidazoles (ketoconazole); other antifungal agents (itraconazole, voriconazole,
posaconazole); protease inhibitors (ritonavir, nelfinavir), macrolides (clarithromycin, erythromycin,
telithromycine). Concomitant use of those drugs with toremifene should be carefully considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) nelfinavir (HOS-084520) clarithromycin (HOS-084517) erythromycin (HOS-084514) ketoconazole (HOS-084513) itraconazole (HOS-084516) voriconazole (HOS-084524) posaconazole (HOS-085622) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-30T12:24:00Z · SHA-256 3b25a11bbd424fca19782652cfc8662dd4db79f69f35943c40313fed13e66e0e · Passage 685a49cc637468e295a54afd3fa92b51d9800204c6cb80df9af06b295ec124ed · Zeichen 1457–1947 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 18
HOS-086275 · Präparat HOS-083284
Erythromycin, itraconazole Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits
CYP3A4 and as a result is expected to increase the plasma concentrations of
erythromycin and itraconazole. Careful monitoring of therapeutic and adverse
effects is recommended when erythromycin or itraconazole is used concomitantly
administered with ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): erythromycin (HOS-084514) itraconazole (HOS-084516)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 34e15249a9e86119c2121b39ffe878deb1186f8eae1df097a84030d4464bdab2 · Zeichen 36093–36643 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 50
HOS-086454 · Präparat HOS-083284
Erythromycin, itraconazole Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits
CYP3A4 and as a result is expected to increase the plasma concentrations of
erythromycin and itraconazole. Careful monitoring of therapeutic and adverse effects is
recommended when erythromycin or itraconazole is used concomitantly administered
with ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): erythromycin (HOS-084514) itraconazole (HOS-084516)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 17a15784195cab7e8c835f897e572f8e0b31a85b7f41617bac90c2209f0f9d53 · Zeichen 37132–37662 im Abschnitt
Wechselwirkungen · Glivec
Glivec 100 mg film-coated tablets Glivec 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-110215 · Präparat HOS-093339
Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. protease inhibitors
such as indinavir, lopinavir/ritonavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole
antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides such
as erythromycin, clarithromycin and telithromycin) could decrease metabolism and increase imatinib
concentrations. There was a significant increase in exposure to imatinib (the mean Cmax and AUC of
imatinib rose by 26% and 40%, respectively) in healthy subjects when it was co-administered with a
single dose of ketoconazole (a CYP3A4 inhibitor). Caution should be taken when administering
Glivec with inhibitors of the CYP3A4 family.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clarithromycin (HOS-084517) telithromycin (HOS-084523) protease (HOS-085623) indinavir (HOS-084518) lopinavir (HOS-086269) ritonavir (HOS-084521) saquinavir (HOS-084522) telaprevir (HOS-090618) nelfinavir (HOS-084520) boceprevir (HOS-090617) ketoconazole (HOS-084513) itraconazole (HOS-084516) posaconazole (HOS-085622) voriconazole (HOS-084524) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-12T09:28:00Z · SHA-256 838bc114dc50fcc5141e52ce7cbac64366b6fd4a03bb5a5e7a5ec09cf8be0b00 · Passage 8b33adeac7a33ce76a3ed583287cd02ab3b3048c12d43838a030dbd58a7f3ff4 · Zeichen 68–805 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 20
HOS-111297 · Präparat HOS-093485
Cytochrome P450 inhibitors
Tadalafil is principally metabolised by CYP3A4. A selective inhibitor of CYP3A4, ketoconazole
(200 mg daily), increased tadalafil (10 mg) exposure (AUC) 2-fold and Cmax by 15 %, relative to the
AUC and Cmax values for tadalafil alone. Ketoconazole (400 mg daily) increased tadalafil (20 mg)
exposure (AUC) 4-fold and Cmax by 22 %. Ritonavir, a protease inhibitor (200 mg twice daily), which
is an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil (20 mg)
exposure (AUC) 2-fold with no change in Cmax. Although specific interactions have not been studied,
other protease inhibitors, such as saquinavir, and other CYP3A4 inhibitors, such as erythromycin,
clarithromycin, itraconazole and grapefruit juice should be co-administered with caution as they would
be expected to increase plasma concentrations of tadalafil (see section 4.4).
Consequently the incidence of the adverse reactions listed in section 4.8 might be increased.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): grapefruit juice (HOS-088787) ketoconazole (HOS-084513) ritonavir (HOS-084521) protease (HOS-085623) saquinavir (HOS-084522) erythromycin (HOS-084514) clarithromycin (HOS-084517) itraconazole (HOS-084516)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 53b9e2340a89f1d59a03722250f75b8d0dc595f65a1a185a08867e88b06cfda4 · Zeichen 301–1275 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 10 mg film-coated tablets CIALIS 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 34–35
HOS-111336 · Präparat HOS-093485
34
AUC and Cmax values for tadalafil alone. Ketoconazole (400 mg daily) increased tadalafil (20 mg)
exposure (AUC) 4-fold and Cmax by 22 %. Ritonavir, a protease inhibitor (200 mg twice daily), which
is an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil (20 mg)
exposure (AUC) 2-fold with no change in Cmax. Although specific interactions have not been studied,
other protease inhibitors, such as saquinavir, and other CYP3A4 inhibitors, such as erythromycin,
clarithromycin, itraconazole and grapefruit juice should be co-administered with caution as they would
be expected to increase plasma concentrations of tadalafil (see section 4.4).
Consequently the incidence of the adverse reactions listed in section 4.8 might be increased.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) ritonavir (HOS-084521) protease (HOS-085623) saquinavir (HOS-084522) erythromycin (HOS-084514) clarithromycin (HOS-084517) itraconazole (HOS-084516) grapefruit juice (HOS-088787)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 496d2586435e56945a5b47b4ba3fc23de03c2fefcb3cca9a8cef5e16b90aa2c2 · Zeichen 574–1331 im Abschnitt
Gegenanzeigen · Procoralan
Procoralan 5 mg film-coated tablets Procoralan 7.5 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-113843 · Präparat HOS-093985
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
- Resting heart rate below 70 beats per minute prior to treatment
- Cardiogenic shock
- Acute myocardial infarction
- Severe hypotension (< 90/50 mmHg)
- Severe hepatic insufficiency
- Sick sinus syndrome
- Sino-atrial block
- Unstable or acute heart failure
- Pacemaker dependent (heart rate imposed exclusively by the pacemaker)
- Unstable angina
- AV-block of 3rd degree
- Combination with strong cytochrome P450 3A4 inhibitors such as azole antifungals
(ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin per os,
josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone (see
sections 4.5 and 5.2)
- Combination with verapamil or diltiazem which are moderate CYP3A4 inhibitors with heart
rate reducing properties (see section 4.5)
- Pregnancy, lactation and women of childbearing potential not using appropriate contraceptive
measures (see section 4.6)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) verapamil (HOS-090602) ketoconazole (HOS-084513) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) josamycin (HOS-113844) telithromycin (HOS-084523) protease (HOS-085623) nelfinavir (HOS-084520) ritonavir (HOS-084521) nefazodone (HOS-084519)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T17:49:00Z · SHA-256 603a04f5264f2cd02119b9fdddd8869a5b599fbe491c4482b048613e56f12c88 · Passage 038375aab2cfa48edaa49949d6504dd4b3dd7e1bb3de22461a40ede8afbd9e21 · Zeichen 0–1101 im Abschnitt
Wechselwirkungen · Procoralan
Procoralan 5 mg film-coated tablets Procoralan 7.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-113857 · Präparat HOS-093985
Potent CYP3A4 inhibitors
The concomitant use of potent CYP3A4 inhibitors such as azole antifungals (ketoconazole,
itraconazole), macrolide antibiotics (clarithromycin, erythromycin per os, josamycin, telithromycin),
HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone is contraindicated (see section 4.3). The
potent CYP3A4 inhibitors ketoconazole (200 mg once daily) and josamycin (1 g twice daily)
increased ivabradine mean plasma exposure by 7 to 8 fold.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) josamycin (HOS-113844) telithromycin (HOS-084523) protease (HOS-085623) nelfinavir (HOS-084520) ritonavir (HOS-084521) nefazodone (HOS-084519)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T17:49:00Z · SHA-256 603a04f5264f2cd02119b9fdddd8869a5b599fbe491c4482b048613e56f12c88 · Passage aeaa075c35dab068c8abda0e4149b350417abc81fdb40d791dd92a17cfbddc6b · Zeichen 1885–2353 im Abschnitt
Gegenanzeigen · Corlentor
Corlentor 5 mg film-coated tablets Corlentor 7.5 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-113882 · Präparat HOS-093993
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
- Resting heart rate below 70 beats per minute prior to treatment
- Cardiogenic shock
- Acute myocardial infarction
- Severe hypotension (< 90/50 mmHg)
- Severe hepatic insufficiency
- Sick sinus syndrome
- Sino-atrial block
- Unstable or acute heart failure
- Pacemaker dependent (heart rate imposed exclusively by the pacemaker)
- Unstable angina
- AV-block of 3rd degree
- Combination with strong cytochrome P450 3A4 inhibitors such as azole antifungals
(ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin per os,
josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone (see
sections 4.5 and 5.2)
- Combination with verapamil or diltiazem which are moderate CYP3A4 inhibitors with heart
rate reducing properties (see section 4.5)
- Pregnancy, lactation and women of childbearing potential not using appropriate contraceptive
measures (see section 4.6)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) josamycin (HOS-113844) telithromycin (HOS-084523) protease (HOS-085623) nelfinavir (HOS-084520) ritonavir (HOS-084521) nefazodone (HOS-084519) verapamil (HOS-090602) diltiazem (HOS-086288) ketoconazole (HOS-084513)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T17:03:00Z · SHA-256 d87e68351dedcde32d83ee33c2f0d9205f341c44bb5b4d122f4a04ffba50a0e0 · Passage 038375aab2cfa48edaa49949d6504dd4b3dd7e1bb3de22461a40ede8afbd9e21 · Zeichen 0–1101 im Abschnitt
Wechselwirkungen · Corlentor
Corlentor 5 mg film-coated tablets Corlentor 7.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-113891 · Präparat HOS-093993
Potent CYP3A4 inhibitors
The concomitant use of potent CYP3A4 inhibitors such as azole antifungals (ketoconazole,
itraconazole), macrolide antibiotics (clarithromycin, erythromycin per os, josamycin, telithromycin),
HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone is contraindicated (see section 4.3). The
potent CYP3A4 inhibitors ketoconazole (200 mg once daily) and josamycin (1 g twice daily)
increased ivabradine mean plasma exposure by 7 to 8 fold.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) josamycin (HOS-113844) telithromycin (HOS-084523) protease (HOS-085623) nelfinavir (HOS-084520) ritonavir (HOS-084521) nefazodone (HOS-084519)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T17:03:00Z · SHA-256 d87e68351dedcde32d83ee33c2f0d9205f341c44bb5b4d122f4a04ffba50a0e0 · Passage aeaa075c35dab068c8abda0e4149b350417abc81fdb40d791dd92a17cfbddc6b · Zeichen 1885–2353 im Abschnitt
Wechselwirkungen · Revatio
Revatio 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-114937 · Präparat HOS-094193
The most potent of the CYP3A4 inhibitors such as ketoconazole and itraconazole would be expected
to have effects similar to ritonavir (see section 4.3). CYP3A4 inhibitors like clarithromycin,
telithromycin and nefazodone are expected to have an effect in between that of ritonavir and CYP3A4
inhibitors like saquinavir or erythromycin, a seven-fold increase in exposure is assumed. Therefore
dose adjustments are recommended when using CYP3A4 inhibitors (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) ritonavir (HOS-084521) clarithromycin (HOS-084517) telithromycin (HOS-084523) nefazodone (HOS-084519) saquinavir (HOS-084522) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 1f4082a0a6c5d963b63edd22c10b5845b86bc5ff94e6467a165f0531de78d7d3 · Zeichen 4967–5439 im Abschnitt
Wechselwirkungen · Revatio
Revatio 0.8 mg/ml solution for injection · Abschnitt 4.5 · PDF-Seite 27
HOS-115000 · Präparat HOS-094193
The most potent of the CYP3A4 inhibitors such as ketoconazole and itraconazole would be expected
to have effects similar to ritonavir (see section 4.3). CYP3A4 inhibitors like clarithromycin,
telithromycin and nefazodone) are expected to have an effect in between that of ritonavir and CYP3A4
inhibitors like saquinavir or erythromycin), a seven-fold increase in exposure is assumed. Therefore
dose adjustments are recommended when using CYP3A4 inhibitors (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): erythromycin (HOS-084514) ketoconazole (HOS-084513) itraconazole (HOS-084516) ritonavir (HOS-084521) clarithromycin (HOS-084517) telithromycin (HOS-084523) nefazodone (HOS-084519) saquinavir (HOS-084522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 481e2c48b4ed56e7321ea948ced45ad338971875626824dcfd615cb657e68f00 · Zeichen 5715–6189 im Abschnitt
Wechselwirkungen · Revatio
Revatio 10 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 45
HOS-115058 · Präparat HOS-094193
The most potent of the CYP3A4 inhibitors such as ketoconazole and itraconazole would be expected
to have effects similar to ritonavir (see section 4.3). CYP3A4 inhibitors like clarithromycin,
telithromycin and nefazodone are expected to have an effect in between that of ritonavir and CYP3A4
inhibitors like saquinavir or erythromycin, a seven-fold increase in exposure is assumed. Therefore
dose adjustments are recommended when using CYP3A4 inhibitors (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) clarithromycin (HOS-084517) telithromycin (HOS-084523) nefazodone (HOS-084519) saquinavir (HOS-084522) erythromycin (HOS-084514) ketoconazole (HOS-084513) itraconazole (HOS-084516)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 1f4082a0a6c5d963b63edd22c10b5845b86bc5ff94e6467a165f0531de78d7d3 · Zeichen 4968–5440 im Abschnitt
Wechselwirkungen · Sutent
Sutent 12.5 mg hard capsules Sutent 25 mg hard capsules Sutent 37.5 mg hard capsules Sutent 50 mg hard capsules · Abschnitt 4.5 · PDF-Seite 9
HOS-115658 · Präparat HOS-094337
Administration of sunitinib with potent CYP3A4 inhibitors (e.g., ritonavir, itraconazole, erythromycin,
clarithromycin, grapefruit juice) may increase sunitinib concentrations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) itraconazole (HOS-084516) erythromycin (HOS-084514) clarithromycin (HOS-084517) grapefruit juice (HOS-088787)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-10T16:28:00Z · SHA-256 d4826c56622b44e469b640c130fb21e1e289d4b954183f420d9e8d3bf8379fe6 · Passage 6772dd2f290f7e6afea05e6d238fe24b1831b765067633d3f2abf096a0be20dc · Zeichen 509–685 im Abschnitt
Wechselwirkungen · Sprycel
SPRYCEL 20 mg film-coated tablets SPRYCEL 50 mg film-coated tablets SPRYCEL 70 mg film-coated tablets SPRYCEL 80 mg film-coated tablets SPRYCEL 100 mg film-coated tablets SPRYCEL 140 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-116681 · Präparat HOS-094467
Active substances that may increase dasatinib plasma concentrations
In vitro studies indicate that dasatinib is a CYP3A4 substrate. Concomitant use of dasatinib and
medicinal products or substances which potently inhibit CYP3A4 (e.g. ketoconazole, itraconazole,
erythromycin, clarithromycin, ritonavir, telithromycin, grapefruit juice) may increase exposure to
dasatinib. Therefore, in patients receiving dasatinib, systemic administration of a potent CYP3A4
inhibitor is not recommended (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): erythromycin (HOS-084514) clarithromycin (HOS-084517) ritonavir (HOS-084521) telithromycin (HOS-084523) grapefruit juice (HOS-088787) ketoconazole (HOS-084513) itraconazole (HOS-084516)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T12:05:00Z · SHA-256 c065657005bf3f51d58db1cb5b29a1453d36e1fc897c0adb5e47ed684f07722e · Passage 4b7cd825bd806fe7cb0d08d7e8a48b7de39787bee3636b13d11149364312873c · Zeichen 0–506 im Abschnitt
Wechselwirkungen · Sprycel
SPRYCEL 10 mg/mL powder for oral suspension · Abschnitt 4.5 · PDF-Seite 47
HOS-116736 · Präparat HOS-094467
Active substances that may increase dasatinib plasma concentrations
In vitro studies indicate that dasatinib is a CYP3A4 substrate. Concomitant use of dasatinib and
medicinal products or substances which potently inhibit CYP3A4 (e.g. ketoconazole, itraconazole,
erythromycin, clarithromycin, ritonavir, telithromycin, grapefruit juice) may increase exposure to
dasatinib. Therefore, in patients receiving dasatinib, systemic administration of a potent CYP3A4
inhibitor is not recommended (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): erythromycin (HOS-084514) clarithromycin (HOS-084517) ritonavir (HOS-084521) telithromycin (HOS-084523) grapefruit juice (HOS-088787) itraconazole (HOS-084516) ketoconazole (HOS-084513)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T12:05:00Z · SHA-256 c065657005bf3f51d58db1cb5b29a1453d36e1fc897c0adb5e47ed684f07722e · Passage 4b7cd825bd806fe7cb0d08d7e8a48b7de39787bee3636b13d11149364312873c · Zeichen 0–506 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10–11
HOS-116802 · Präparat HOS-094481
10
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics neurotoxicity, QT prolongation) is unavoidable, consider
(e.g., telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, [see section 4.4]. the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors tacrolimus levels may occur, as tacrolimus the next day at a
(e.g., ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase > 5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with tacrolimus exposure may increase needed based on tacrolimus
and without dasabuvir), > 50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, The effect on tacrolimus blood first few days) and re-
ceritinib. concentrations may remain for evaluated on and after
Strong interactions have also several days after co-administration completion of the CYP3A4
been observed with the is completed. inhibitor. Upon completion,
macrolide antibiotic appropriate dose and dosing
erythromycin frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), prolongation) [see section 4.4]. A administration. Reduce
the macrolide antibiotics rapid increase in tacrolimus level tacrolimus dose if needed [see
(e.g., azithromycin), calcium may occur. section 4.2]. Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol,
lansoprazole, omeprazole,
the HCV antivirals
elbasvir/grazoprevir and
glecaprevir/pibrentasvir, the
CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib,
crizotinib and imatinib and
(Chinese) herbal remedies
containing extracts of
Schisandra sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) itraconazole (HOS-084516) posaconazole (HOS-085622) voriconazole (HOS-084524) telithromycin (HOS-084523) troleandomycin (HOS-090575) clarithromycin (HOS-084517) josamycin (HOS-113844) protease (HOS-085623) ritonavir (HOS-084521) nelfinavir (HOS-084520) saquinavir (HOS-084522) telaprevir (HOS-090618) boceprevir (HOS-090617) ombitasvir (HOS-110300) paritaprevir (HOS-110301) dasabuvir (HOS-110302) nefazodone (HOS-084519) cobicistat (HOS-088111) idelalisib (HOS-116811) ceritinib (HOS-086215) erythromycin (HOS-084514) fluconazole (HOS-087945) isavuconazole (HOS-085186) clotrimazole (HOS-090574) miconazole (HOS-115630) azithromycin (HOS-088112) calcium (HOS-085615) nifedipine (HOS-086289) nicardipine (HOS-090619) diltiazem (HOS-086288) verapamil (HOS-090602) amiodarone (HOS-085596) danazol (HOS-085473) lansoprazole (HOS-085166) omeprazole (HOS-085912) elbasvir (HOS-108814) grazoprevir (HOS-108815) glecaprevir (HOS-086297) pibrentasvir (HOS-086298) letermovir (HOS-090621) tyrosine (HOS-108875) nilotinib (HOS-086218) crizotinib (HOS-116818) imatinib (HOS-110212)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 871fa2c72a31ddd6873cbb2f1b3b0dd9ad898b46eba141ac32a052a178cc3bc9 · Zeichen 3910–8415 im Abschnitt
Wechselwirkungen · Abraxane
Abraxane 5 mg/ml powder for dispersion for infusion. · Abschnitt 4.5 · PDF-Seite 9
HOS-117861 · Präparat HOS-094711
The metabolism of paclitaxel is catalysed, in part, by cytochrome P450 isoenzymes CYP2C8 and
CYP3A4 (see section 5.2). Therefore, in the absence of a PK drug-drug interaction study, caution
should be exercised when administering paclitaxel concomitantly with medicines known to inhibit
either CYP2C8 or CYP3A4 (e.g. ketoconazole and other imidazole antifungals, erythromycin,
fluoxetine, gemfibrozil, clopidogrel, cimetidine, ritonavir, saquinavir, indinavir, and nelfinavir)
because toxicity of paclitaxel may be increased due to higher paclitaxel exposure. Administering
paclitaxel concomitantly with medicines known to induce either CYP2C8 or CYP3A4 (e.g. rifampicin,
carbamazepine, phenytoin, efavirenz, nevirapine) is not recommended because efficacy may be
compromised because of lower paclitaxel exposures.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) ritonavir (HOS-084521) saquinavir (HOS-084522) indinavir (HOS-084518) nelfinavir (HOS-084520) carbamazepine (HOS-085618) phenytoin (HOS-084531) efavirenz (HOS-087947) nevirapine (HOS-088064) ketoconazole (HOS-084513) imidazole (HOS-117862) erythromycin (HOS-084514) fluoxetine (HOS-085946) gemfibrozil (HOS-088403) clopidogrel (HOS-087927)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-21T09:38:00Z · SHA-256 38c462aa5de60951dcb4be6132b86a26b536e6a1309509e0d2888dd17f8022aa · Passage f250f391b1f7f31d44e77cb1f0e86c8273e473bb0bc0fc63253f2b40dbd561f3 · Zeichen 0–813 im Abschnitt
Wechselwirkungen · Instanyl
Instanyl 50 micrograms/dose nasal spray, solution Instanyl 100 micrograms/dose nasal spray, solution Instanyl 200 micrograms/dose nasal spray, solution · Abschnitt 4.5 · PDF-Seite 7
HOS-120558 · Präparat HOS-095157
Fentanyl is metabolised mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4),
therefore potential interactions may occur when Instanyl is given concurrently with medicinal products
that affect CYP3A4 activity. Coadministration with medicinal products that induce 3A4 activity may
reduce the efficacy of Instanyl. The concomitant use of Instanyl with strong CYP3A4 inhibitors (e.g.
ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate
CYP3A4 inhibitors (e.g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir,
and verapamil) may result in increased fentanyl plasma concentrations, potentially causing serious
adverse drug reactions including fatal respiratory depression.
Patients receiving Instanyl concomitantly with moderate or strong CYP3A4 inhibitors should be
carefully monitored for an extended period of time. Dose increase should be done with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clarithromycin (HOS-084517) nelfinavir (HOS-084520) amprenavir (HOS-086183) aprepitant (HOS-112506) diltiazem (HOS-086288) erythromycin (HOS-084514) fluconazole (HOS-087945) fosamprenavir (HOS-086182) verapamil (HOS-090602) ritonavir (HOS-084521) ketoconazole (HOS-084513) itraconazole (HOS-084516) troleandomycin (HOS-090575)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T14:16:00Z · SHA-256 c62f47d72fc641986d789e1b677e3be39ccd613b0c706fbcdbe36063f292309f · Passage 5c9d8fc4948ebac2552fc912d78e14775b0ca4461a94126b50e09135530da315 · Zeichen 644–1590 im Abschnitt
Wechselwirkungen · Instanyl
Instanyl 50 micrograms nasal spray, solution in single-dose container Instanyl 100 micrograms nasal spray, solution in single-dose container Instanyl 200 micrograms nasal spray, solution in single-dose container · Abschnitt 4.5 · PDF-Seite 20
HOS-120583 · Präparat HOS-095157
Fentanyl is metabolised mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4),
therefore potential interactions may occur when Instanyl is given concurrently with medicinal products
that affect CYP3A4 activity. Coadministration with medicinal products that induce 3A4 activity may
reduce the efficacy of Instanyl. The concomitant use of Instanyl with strong CYP3A4 inhibitors (e.g.
ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate
CYP3A4 inhibitors (e.g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir,
and verapamil) may result in increased fentanyl plasma concentrations, potentially causing serious
adverse drug reactions including fatal respiratory depression.
Patients receiving Instanyl concomitantly with moderate or strong CYP3A4 inhibitors should be
carefully monitored for an extended period of time. Dose increase should be done with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): troleandomycin (HOS-090575) clarithromycin (HOS-084517) nelfinavir (HOS-084520) amprenavir (HOS-086183) aprepitant (HOS-112506) diltiazem (HOS-086288) erythromycin (HOS-084514) fluconazole (HOS-087945) fosamprenavir (HOS-086182) verapamil (HOS-090602) ritonavir (HOS-084521) ketoconazole (HOS-084513) itraconazole (HOS-084516)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T14:16:00Z · SHA-256 c62f47d72fc641986d789e1b677e3be39ccd613b0c706fbcdbe36063f292309f · Passage 5c9d8fc4948ebac2552fc912d78e14775b0ca4461a94126b50e09135530da315 · Zeichen 644–1590 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.